Compare Clorox Co (CLX) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Clorox Co vs Davita Inc — how do they compare? Clorox Co trades at $108.39 (market cap $13.02B), while Davita Inc trades at $178.35 (market cap $11.72B). The key difference: Clorox Co and Davita Inc are close in size by market cap, and Clorox Co pays a 4.64% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| CLX | DVA | |
|---|---|---|
Market Cap | $13.02B | $11.72B |
Sector | Consumer Staples | Health |
52-Week High | $127.16 | $240.96 |
52-Week Low | $86.12 | $103.87 |
Enterprise Value | $18.40B | $24.44B |
Dividend Yield | 4.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Clorox (CLX) trades at $105.15, down 0.43% today, with a bullish technical signal from moving averages and strong momentum indicators. Recent Q2 2026 earnings beat expectations with EPS of $1.66, though Q4 2025 missed. The company reported fiscal 2025 revenue of $7.10 billion and net income of $810 million, with a high ROE of 285.64% but elevated P/B ratio of 141.28. Dividend increased to $1.25 per share, payable August 28, 2026.
Outlook is mixed: bullish technicals and profitability contrast with analyst caution (10.34% buy ratings) and a consensus price target of $97.50 below current price. Risks include inflation pressures and competitive threats from private labels. Upside hinges on execution of cost-saving initiatives and market share recovery.
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
